How much revenue does Sorrento Therapeutics make?

Sorrento Therapeutics reported $62.84 million in revenue for fiscal year 2022, up 18.8% from $52.90 million in fiscal year 2021. In Q2 2023 revenue was $15.03 million.

What is Sorrento Therapeutics's largest business segment?

Scilex, with $38.03 million or 61% of segment revenue in fiscal year 2022. Next: Sorrento Therapeutics (39%).

What companies are similar to Sorrento Therapeutics?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sybleu Inc. (SYBE), Cantabio Pharmaceuticals, Inc. (CTBO), Synovics Pharmaceuticals, Inc. (SYVC), Viracta Therapeutics, Inc. (VIRX).

Sorrento Therapeutics, Inc. (SRNE) Stock

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, includin...

At a glance

Sorrento Therapeutics reported revenue of $62.84 million for fiscal year 2022, up 18.8% from fiscal year 2021, and net income of -$572.84 million. In Q2 2023 (the quarter ended June 30, 2023) revenue was $15.03 million, up 31.1% from a year before. Its largest business segment, Scilex, brought in 61% of segment revenue in fiscal year 2022.

Figures from company filings; latest fiscal year ended December 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.